Anavex Life Sciences (AVXL) investor relations material

Key scientific and clinical insights

• Focus on oral, personalized treatments for CNS diseases, especially Alzheimer's and dementia, addressing a major unmet need.

• Phase IIb/III trial of blarcamesine showed 36% improvement in ADAS-Cog13, rising to nearly 50% in a pre-specified population over 48 weeks.

• Reliable safety profile with no ARIA or drug-related deaths, and significant slowing of brain atrophy observed.

• Biomarker outcomes, including plasma Abeta 42 ratio, corroborated clinical results.

• Mechanism centers on restoring autophagy and reducing cellular stress, with genetic precision medicine approaches enhancing efficacy.

Pipeline and development plans

• Pipeline includes blarcamesine for Alzheimer's, Parkinson's disease dementia, Rett syndrome, Fragile X, and other rare CNS disorders.

• ANAVEX 3-71 completed phase II in schizophrenia, with plans to advance in frontotemporal dementia.

• Upcoming milestones: EMA re-examination review, new Alzheimer's and Parkinson's studies, and three imminent publications.

• Precision medicine findings highlight COL24A1 and sigma-1 wild type genes as key to optimal response.

• Plans for further studies in Fragile X, rare diseases, and preclinical work in infantile spasm and Angelman syndrome.

Commercial and operational highlights

• Oral formulation offers convenience for patients and caregivers, reducing logistical and financial burdens.

• No debt, over $131 million in cash, and a projected runway of more than three years.

• Strong IP protection through 2040 and non-dilutive funding from major foundations.

• Targeting large markets in the US and Europe for Alzheimer's, Parkinson's, schizophrenia, and rare diseases.

• Engaging with care advisory groups to educate and strategize for patient-centric solutions.